6 Months of Continuing Medical Education

How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.

Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.

Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.

New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.

Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.